Chemotherapy-induced nausea and vomiting prophylaxis in pediatric patients at a teaching hospital: assessment of adherence to guidelines
DOI:
https://doi.org/10.30968/rbfhss.2023.142.0904Abstract
Aims: Describing the adherence rate of antiemetic prophylaxis in pediatric patients using antineoplastic agents and possible associated factors. Methods: It is a retrospective cross-sectional study, which took place in a teaching hospital at Belo Horizonte. There were included pediatric patients that received chemotherapy at the hospital from January to June, 2022. The demographic, clinical and pharmacotherapeutic data were collected from physicians’ prescriptions and patients’ charts. Descriptive analysis was performed and the results were expressed by absolute and relative frequency for categorical variables and by measures of central tendency and dispersion for numeral variables. Univariate analysis was done in order to assess the association between chemotherapy induced nausea and vomiting and exposure variables. It was calculated through Pearson’s chi-square test. It was considered statistically significant a p-value less than 0,05. Results: It was observed that the prescription practice was closer to recommendations made by guidelines of American Society of Clinical Oncology and Multinational Association of Supportive Care in Cancer | European Society of Medical Oncology with 62% of adherence, meanwhile Pediatric Oncology Group of Ontario had 4,6% of concordance. Underuse of antiemetics was the principal reason for discordance. In particular the lack of dexamethasone prescription. It was identified statistically significance association between nausea and vomiting registers and vincristine and cyclophosphamide use. Conclusions: This study detected high adherence to the American Society of Clinical Oncology and Multinational Association of Supportive Care in Cancer | European Society of Medical Oncology guidelines, even though, the number of observed nausea and vomiting events flag up a potential failure in the antiemetic prophylaxis. The associative analyses between nausea and vomiting registers and vincristine and cyclophosphamide use were statistically significant.
Downloads
References
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. doi:10.3322/caac.21660
Simino GPR, Reis IA, Acurcio FA, et al. Risk factors associated with antineoplastic chemotherapy-induced nausea and vomiting. Rev Saude Publica. 2020;54(106):1-13. doi:10.11606/s1518-8787.2020054002178
Phillips RS, Gopaul S, Gibson F, et al. Antiemetic medication for prevention and treatment of chemotherapy induced nausea and vomiting in childhood. Cochrane Database of Systematic Reviews. 2010;(9). doi:10.1002/14651858.cd007786.pub2
McKinnon K, Jupp J, Ghosh S, et al. Adherence to pediatric acute chemotherapy-induced nausea and vomiting guidelines in Canadian hospitals. Pediatr Blood Cancer. 2019;66(1):e27488. doi:10.1002/pbc.27488
Patel P, Robinson PD, Orsey A, et al. Chemotherapy-Induced Nausea and Vomiting Prophylaxis: Practice Within the Children’s Oncology Group. Pediatr Blood Cancer. 2016;63(5):887-892. doi:10.1002/pbc.25915
Sherani F, Boston C, Mba N. Latest Update on Prevention of Acute Chemotherapy-Induced Nausea and Vomiting in Pediatric Cancer Patients. Curr Oncol Rep. 2019;21(10):89. doi:10.1007/s11912-019-0840-0
Jordan K, Roila F, Molassiotis A, et al. Antiemetics in children receiving chemotherapy. MASCC/ESMO guideline update 2009. Supportive Care in Cancer. 2011;19(SUPPL. 1)S37-42. doi:10.1007/s00520-010-0994-7
Navari RM. Nausea and Vomiting in Advanced Cancer. Curr Treat Options Oncol. 2020;21(2):14. doi:10.1007/s11864-020-0704-8
Roila F, Aapro M, Ballatori E, et al. Prevention of chemotherapy- and radiotherapy-induced emesis: Results of the 2004 Perugia International Antiemetic Consensus Conference. Annals of Oncology. 2006;17(1):20-28. doi:10.1093/annonc/mdj078
LeBaron S, Zeltzer LK, LeBaron C, et al. Chemotherapy Side Effects in Pediatric Oncology Patients: Drugs, Age, and Sex as Risk Factors. 1988;16(4):263-268. doi: 10.1002/mpo.2950160408
Holdsworth MT, Raisch DW, Frost J. Acute and delayed nausea and emesis control in pediatric oncology patients. Cancer. 2006;106(4):931-940. doi:10.1002/cncr.21631
Albuquerque AS, Okumura LM, Betin-de-Moraes NR, et al. Pediatric related risk factors in acute and delayed chemotherapy-induced nausea and vomiting: multivariate analysis. Brazilian Journal of Oncology. 2022;18:e-20200292. doi:10.5935/2526-8732.20220292
Patel P, Robinson PD, Thackray J, et al. Guideline for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric cancer patients: A focused update. Pediatr Blood Cancer. 2017;64(10):e26542. doi:10.1002/pbc.26542
Paw Cho Sing E, Robinson PD, Flank J, et al. Classification of the acute emetogenicity of chemotherapy in pediatric patients: A clinical practice guideline. Pediatr Blood Cancer. 2019;66(5):e27646. doi:10.1002/pbc.27646
Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO Guideline Update. 2020; J. Clin. Oncol. 38(24):2782-2797. doi: 10.1200/JCO.20.01296
Dupuis LL, Sung L, Molassiotis A, et al. 2016 updated MASCC/ESMO consensus recommendations: Prevention of acute chemotherapy-induced nausea and vomiting in children. Supportive Care in Cancer. 2017;25(1):323-331. doi:10.1007/s00520-016-3384-y
Jordan K, Chan A, Gralla RJ, et al. 2016 Updated MASCC/ESMO consensus recommendations: Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents. Supportive Care in Cancer. 2017;25(1):271-275. doi:10.1007/s00520-016-3332-x
Bun S, Kunisawa S, Sasaki N, et al. Analysis of concordance with antiemetic guidelines in pediatric, adolescent, and young adult patients with cancer using a large-scale administrative database. Cancer Med. 2019;8(14):6243-6249. doi:10.1002/cam4.2486
Phillips RS, Friend AJ, Gibson F, et al. Antiemetic medication for prevention and treatment of chemotherapy-induced nausea and vomiting in childhood. Cochrane Database of Systematic Reviews. 2016;(2). doi:10.1002/14651858.CD007786.pub3
Beauchemin M, Sung L, Hershman DL, et al. Guideline concordant care for prevention of acute chemotherapy-induced nausea and vomiting in children, adolescents, and young adults. Supportive Care in Cancer. 2020;28(10):4761-4769. doi:10.1007/s00520-020-05310-6
Pulido JZ, Aleixo SB. Antieméticos em oncologia. Rev. Bras. Oncologia Clínica. 2004;1(3):35-40.
Consenso Brasileiro de Náuseas e Vômitos. Rev. Bras. Cuidados Paliativos. 2011;3(3 – suplemento 2).
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Authors
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The authors hereby transfer, assign, or otherwise convey to RBFHSS: (1) the right to grant permission to republish or reprint the stated material, in whole or in part, without a fee; (2) the right to print republish copies for free distribution or sale; and (3) the right to republish the stated material in any format (electronic or printed). In addition, the undersigned affirms that the article described above has not previously been published, in whole or part, is not subject to copyright or other rights except by the author(s), and has not been submitted for publication elsewhere, except as communicated in writing to RHFHSS with this document.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC-BY-NC-ND) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Serlf-archiving policy
This journal permits and encourages authors to post and archive the final pdf of the articles submitted to the journal on personal websites or institutional repositories after publication, while providing bibliographic details that credit its publication in this journal.
